Clinical Trials in Boston

Showing 6461-6480 of 17,836 trials

Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

NCT04458103

Prior studies have shown that left ventricular assist device (LVAD) implantation commonly results in right ventricular failure (RVF). Right ventricular dysfunction and failure after LVAD implantation is known to increase morbidity and mortality and contribute to longer post-implant hospital length of stay. Since RVF is difficult to predict and can have harmful effects such as increased ICU stay, adverse outcomes, and mortality, it could be beneficial to preemptively treat patients through preoperative or intraoperative percutaneous right ventricular assist device (RVAD) placement to prevent RVF. This trial will include both a prospective interventional cohort and a retrospective control cohort. The prospective interventional cohort will consist of patients undergoing LVAD implantation at Massachusetts General Hospital. These patients will preemptively receive an RVAD (either the ProtekDuo or Impella RP) surrounding LVAD implantation. The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past. This group will be matched with the enrolled prospective interventional patients. The purpose of this study is to compare clinical outcomes of standard of care treatment versus percutaneous RVAD placement perioperatively to LVAD implantation. The investigators hypothesize that the use of the RVAD will mitigate need for inotropic support, reducing the vasoactive-inotrope score (VIS) by 50%, and will improve end organ function in patients compared to standard of care. Subjects who consent to the study will undergo peri-operative placement of an RVAD, which will be left in up to 72 hours postoperatively. The type of RVAD (Impella RP or ProtekDuo) inserted will be determined by patient needs and venous access and will be up to the discretion of the treating physician. 25 subjects will be enrolled in the prospective interventional cohort and compared to 25 subjects in the matched retrospective control cohort.

Heart Failure

Massachusetts General Hospital161 participantsStarted May 2020

Boston, Massachusetts, United States

COMPLETEDPhase 3< 1 mile

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

NCT00992459

This was a randomized, active-controlled, double-blind, cross-over study designed to enroll subjects with UCDs who are being treated with NaPBA.

Urea Cycle Disorders

Amgen46 participantsStarted Oct 2009

Long Beach, California, United States • Los Angeles, California, United States • Stanford, California, United States +19 more locations

Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Find Trials by Condition in Boston

Efficacy of Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT

Overcoming Barriers to Accessing Genetic Medicine

TARGET Post-Approval Study

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

IPG Replacement Study (PREFERENCE-H)

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

Clinical Evaluation of the FilmArray® Global Fever (GF) Panel

The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer